

#### **BIBLIOGRAFÍA:**

1. Dafina Petrova et Al. Obesity as a risk factor in COVID-19: Possible mechanisms and implications. Aug-Sep 2020;52(7):496-500. 2020
2. Stagi S et al. Policaptil Gel Retard® significantly reduces body mass index and hyperinsulinism and may decrease the risk of type 2 diabetes mellitus (T2DM) in obese children and adolescents with family history of obesity and T2DM. Italian Journal of Pediatrics, 2015
3. Fornari E et al. Policaptil Gel Retard Intake Reduces Postprandial Triglycerides, Ghrelin and Appetite in Obese Children: A Clinical Trial. Nutrients 2020
4. Studio clinico di efficacia su peso, profilo glicemico, lipidico in soggetti adulti sovrappeso e lievemente obesi – Vettor, Dipartimento di medicina interna, Università di Padova.
5. Studio di efficacia in soggetti adulti sovrappeso e obesi – Del Prato, Dipartimento Endocrinologia e Metabolismo, Sezione di Diabetologia e Malattie Metaboliche Studio di sicurezza in soggetti adulti normopeso – Del Prato, Dipartimento Endocrinologia e Metabolismo, Sezione di Diabetologia e Malattie Metaboliche dell'Ospedale Cisanello di Pisa.
6. Ciccone V. et Al. Efficacy of AdipoDren® in Reducing Interleukin-1-Induced Lymphatic Endothelial Hyperpermeability. J Vasc Res. 2017 Jan; 53(5-6): 255–268.
7. James B Meigs, MD, MPH. Metabolic syndrome (insulin resistance syndrome or syndrome X). Uptodate. Jul 2020.

#### **FUENTES ADICIONALES:**

Los costes económicos de la obesidad y el sobrepeso. Matilde Alonso Pérez (matilde.alonso@univ-lyon2.fr) and Elies Furio Blasco (furio@univ-lyon3.fr)  
L. Cai, J. Lubitz, K. M. Flegal, and E. Pamuk, "The predicted effects of chronic obesity in middle age on medicare costs and mortality," Med Care, vol. 48, no. 6, pp. 510–7, 2010.

